GlassScriptPhysician profile
David H Kim
NPI 1043283401
$1,755.01
in general payments reported to CMS, 2019-2025
25 companies · $450 in 2025
The $450 reported for 2025 was more than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $221 · 2020: $195 · 2021: $46.47 · 2022: $266 · 2023: $191 · 2024: $386 · 2025: $450.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,027.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,026.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $259.18 | 2019-2024 | Opdivo |
| Boston Scientific Corporation | $182.57 | 2020-2025 | Spaceoar Vue System - 10ml |
| Bioprotect Medical, INC. | $164.91 | 2025 | Bioprotect Balloon Implant System |
| Pharmacosmos Therapeutics INC. | $151.86 | 2022-2024 | Monoferric |
| Seagen INC. | $119.93 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $111.15 | 2019-2025 | Airsupra, Lynparza |
| Astellas Pharma US INC | $99.00 | 2020 | |
| Merck Sharp & Dohme LLC | $81.06 | 2019-2025 | Keytruda, Keytruda Qlex |
| Ipsen Biopharmaceuticals, INC | $73.26 | 2021-2024 | Iqirvo |
| Amgen INC. | $68.34 | 2019-2023 | Lumakras |
| Tersera Therapeutics LLC | $67.84 | 2024 | |
| Novartis Pharmaceuticals Corporation | $53.07 | 2025 | |
| Genzyme Corporation | $38.15 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $37.19 | 2025 | Iclusig |
| Puma Biotechnology, INC. | $34.31 | 2019-2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $33.92 | 2025 | Ojjaara |
| Alexion Pharmaceuticals, INC. | $28.05 | 2025 | Ultomiris |
| Janssen Biotech, INC. | $26.17 | 2019-2021 | |
| Blue Earth Diagnostics | $26.05 | 2019 | |
| Pfizer INC. | $23.97 | 2025 | |
| Genentech USA, INC. | $17.62 | 2025 | Venclexta |
| Clovis Oncology, INC. | $15.33 | 2019 | |
| Amag Pharmaceuticals, INC. | $15.00 | 2019 | |
| Lilly USA, LLC | $14.41 | 2023 | Verzenio, Jaypirca |
| Melinta Therapeutics, LLC | $12.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.